近日，Alphabet（谷歌母公司）旗下的AI制药企业Isomorphic Labs宣布与全球制药巨头礼来和诺华建立多靶点战略合作。此次合作旨在研发创新药物，预计为公司带来近30亿美元的价值（不包括未来药物销售可能产生的特许权使用费）。
根据合作协议，双方将重点关注小分子领域，运用AI技术进行药物研发。此次合作有望加速药物研发进程，提高研发效率，为患者带来更多创新疗法。
此次合作的达成，体现了AI技术在制药领域的广泛应用，以及全球制药企业对创新药物研发的重视。随着科技的不断发展，AI制药将成为未来药物研发的重要方向。
Title: AI制药企业Isomorphic Labs与礼来、诺华达成30亿美元战略合作
Keywords: AI pharmaceuticals, Eli Lilly, Novartis, strategic cooperation, small molecules
News content:
Recently, Isomorphic Labs, an AI pharmaceutical company under Alphabet (parent company of Google), announced a multi-target strategic cooperation with global pharmaceutical giants Eli Lilly and Novartis. The cooperation aims to develop innovative drugs and is expected to bring nearly $3 billion in value to the company (excluding possible royalty revenues from future drug sales).
According to the cooperation agreement, the two parties will focus on the field of small molecules and use AI technology for drug development. This cooperation is expected to accelerate the drug development process and improve efficiency, bringing more innovative therapies to patients.
The establishment of this cooperation demonstrates the widespread application of AI technology in the pharmaceutical industry and the importance of innovative drug development for global pharmaceutical companies. With the continuous development of technology, AI pharmaceuticals will become an important direction for future drug development.
【来源】https://news.cnstock.com/industry,rdjj-202401-5173731.htm
Views: 1